China Shineway Pharmaceutical Group Limited Working Capital to Net Assets Ratio
China Shineway Pharmaceutical Group Limited working capital to net assets ratio. China Shineway Pharmaceutical Group Limited (C1S) has a Working Capital to Net Assets ratio of 84.3% as of December 2025. Working capital of €6.79 Billion (current assets of €9.30 Billion minus current liabilities of €2.51 Billion) is measured against net assets of €8.06 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is China Shineway Pharmaceutical Group Limi's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of China Shineway Pharmaceutical Group Limited (2013–2025)
Working capital to net assets ratio of China Shineway Pharmaceutical Group Limited from 2013 to 2025. This chart shows how China Shineway Pharmaceutical Group Limited's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the ratio stands at 84.3%, reflecting working capital of €6.79 Billion against net assets of €8.06 Billion EUR. See C1S defensive interval ratio to measure how many days the company can operate on defensive assets alone.
China Shineway Pharmaceutical Group Limited Working Capital to Net Assets Ratio by Year (2013–2025)
China Shineway Pharmaceutical Group Limited working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for China Shineway Pharmaceutical Group Limited from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is China Shineway Pharmaceutical Group Limi's balance sheet.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 84.3% | €6.79 Billion | €8.06 Billion | €9.30 Billion | €2.51 Billion | ▲ +1.9 pp |
| 2024 | 82.3% | €6.15 Billion | €7.47 Billion | €8.60 Billion | €2.45 Billion | ▲ +1.0 pp |
| 2023 | 81.3% | €5.72 Billion | €7.03 Billion | €8.15 Billion | €2.43 Billion | ▲ +1.2 pp |
| 2022 | 80.2% | €5.12 Billion | €6.38 Billion | €6.78 Billion | €1.67 Billion | ▲ +2.2 pp |
| 2021 | 78.0% | €4.60 Billion | €5.90 Billion | €5.70 Billion | €1.10 Billion | ▲ +3.3 pp |
| 2020 | 74.6% | €4.32 Billion | €5.79 Billion | €5.52 Billion | €1.19 Billion | ▲ +5.0 pp |
| 2019 | 69.7% | €4.03 Billion | €5.78 Billion | €5.20 Billion | €1.18 Billion | ▲ +2.5 pp |
| 2018 | 67.2% | €3.87 Billion | €5.77 Billion | €4.65 Billion | €780.27 Million | ▲ +1.0 pp |
| 2017 | 66.2% | €3.85 Billion | €5.82 Billion | €4.56 Billion | €709.29 Million | ▲ +2.6 pp |
| 2016 | 63.6% | €3.58 Billion | €5.63 Billion | €4.25 Billion | €673.06 Million | ▲ +4.3 pp |
| 2015 | 59.3% | €3.14 Billion | €5.30 Billion | €3.84 Billion | €701.61 Million | ▼ -3.3 pp |
| 2014 | 62.6% | €3.06 Billion | €4.89 Billion | €3.95 Billion | €885.99 Million | ▲ +1.7 pp |
| 2013 | 60.9% | €2.70 Billion | €4.43 Billion | €3.88 Billion | €1.18 Billion | — |